P63 Cost Effectiveness of Cabozantinib Plus Nivolumab As First-Line Treatment for Renal Cell Carcinoma
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.081
https://www.valueinhealthjournal.com/article/S1098-3015(22)00282-0/fulltext
Title :
P63 Cost Effectiveness of Cabozantinib Plus Nivolumab As First-Line Treatment for Renal Cell Carcinoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00282-0&doi=10.1016/j.jval.2022.04.081
First page :
Section Title :
Open access? :
No
Section Order :
10065